WallStreetZenWallStreetZen

NYSEMKT: CATX
Perspective Therapeutics Inc Stock

$0.64-0.03 (-4.48%)
Updated Mar 24, 2023
CATX Price
$0.64
Fair Value Price
N/A
Market Cap
$90.95M
52 Week Low
$0.19
52 Week High
$0.67
P/E
-10.67x
P/B
1.58x
P/S
3.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.95M
Earnings
-$9.10M
Gross Margin
40.2%
Operating Margin
-91.45%
Profit Margin
-91.4%
Debt to Equity
0.08
Operating Cash Flow
-$7M
Beta
0.61
Next Earnings
May 11, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CATX Overview

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 43 full-time employees. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The firm is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The firm's Proxcelan Cesium-131 seed is classified as a Class II device.

Zen Score

Industry Average (33)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CATX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CATX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CATX is good value based on its book value relative to its share price (1.58x), compared to the US Medical Instruments & Supplies industry average (3.48x)
P/B vs Industry Valuation
CATX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CATX due diligence checks available for Premium users.

Be the first to know about important CATX news, forecast changes, insider trades & much more!

Valuation

CATX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-10.67x
Industry
23.41x
Market
21.37x

CATX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.58x
Industry
3.48x
CATX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CATX's financial health

Profit margin

Revenue
$1.7M
Net Income
-$4.1M
Profit Margin
-236.9%
CATX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CATX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$62.5M
Liabilities
$4.8M
Debt to equity
0.08
CATX's short-term assets ($57.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CATX's short-term assets ($57.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CATX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CATX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.8M
Investing
-$35.2M
Financing
$28.0k
CATX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CATX vs Medical Stocks

TickerMarket Cap1d %P/EP/B
CATX$90.95M-4.48%-10.67x1.58x
OMIC$79.14M-6.78%-0.86x0.30x
PLSE$104.98M-6.00%-1.39x16.96x
MLSS$64.21M+0.99%-7.67x5.64x
PDEX$60.25M0.00%15.89x2.46x

Perspective Therapeutics Stock FAQ

What is Perspective Therapeutics's quote symbol?

NYSEMKT: CATX) Perspective Therapeutics trades on the NYSEMKT under the ticker symbol CATX. Perspective Therapeutics stock quotes can also be displayed as NYSEMKT: CATX.

If you're new to stock investing, here's how to buy Perspective Therapeutics stock.

What is the 52 week high and low for Perspective Therapeutics (NYSEMKT: CATX)?

(NYSEMKT: CATX) Perspective Therapeutics's 52-week high was $0.67, and its 52-week low was $0.19. It is currently -4.9% from its 52-week high and 233.33% from its 52-week low.

How much is Perspective Therapeutics stock worth today?

(NYSEMKT: CATX) Perspective Therapeutics currently has 142,112,766 outstanding shares. With Perspective Therapeutics stock trading at $0.64 per share, the total value of Perspective Therapeutics stock (market capitalization) is $90.95M.

Perspective Therapeutics stock was originally listed at a price of $5.10 in Nov 10, 2005. If you had invested in Perspective Therapeutics stock at $5.10, your return over the last 17 years would have been -87.45%, for an annualized return of -11.49% (not including any dividends or dividend reinvestments).

How much is Perspective Therapeutics's stock price per share?

(NYSEMKT: CATX) Perspective Therapeutics stock price per share is $0.64 today (as of Mar 24, 2023).

What is Perspective Therapeutics's Market Cap?

(NYSEMKT: CATX) Perspective Therapeutics's market cap is $90.95M, as of Mar 27, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Perspective Therapeutics's market cap is calculated by multiplying CATX's current stock price of $0.64 by CATX's total outstanding shares of 142,112,766.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.